Literature DB >> 18294108

In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Raymond Cha1.   

Abstract

STUDY
OBJECTIVE: To evaluate the activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli.
DESIGN: In vitro susceptibility and time-kill analysis.
SETTING: University-affiliated research laboratory. ISOLATES: Ten K. pneumoniae and 10 E. coli clinical strains known to produce ESBL.
MEASUREMENTS AND MAIN RESULTS: Minimum inhibitory concentration (MIC) testing was performed at 5.5 and 7.0 log(10) colony-forming units (cfu)/ml. Time-kill studies were performed over 24 hours with a high inoculum of 7.0 log(10) cfu/ml for cefepime, imipenem, tigecycline, and gentamicin at 1 times MIC. Combination studies were tested for cefepime plus tigecycline, cefepime plus imipenem, imipenem plus tigecycline, and for adjunctive gentamicin with cefepime, imipenem, or tigecycline. At the high inoculum, the MIC ranges for cefepime, imipenem, tigecycline, and gentamicin were 0.25-256 (MIC for 90% of tested strains [MIC(90)] = 32), 0.125-2 (MIC(90) = 1), 0.25-16 (MIC(90) = 4), and 0.25-4 mg/L (MIC(90) = 1), respectively, for all isolates. At the higher inoculum, MICs shifted for cefepime, imipenem, and tigecycline. Change in log(10) cfu/ml from baseline to 24 hours for cefepime, imipenem, and tigecycline alone ranged from 4.85-0.71, 5-4.22, and 3.5-1.01, respectively, for all isolates. Bactericidal activity was observed for cefepime alone (10 [50%] of 20 isolates), imipenem alone (20 [100%] of 20), and tigecycline alone (3 [15%] of 20). Combination studies with cefepime plus tigecycline resulted in synergy against 4 (20%) of 20 isolates. Combination studies with gentamicin resulted in synergy against 6 isolates (30%) with cefepime and 4 isolates (20%) with tigecycline. No synergy was observed with imipenem combinations. No antagonism was observed. With the exception of cefepime, correlations were observed between MIC and terminal densities for studied agents.
CONCLUSIONS: Cefepime exhibited bactericidal activity but was unrelated to susceptibility. Tigecycline exhibited predictable bacteriostatic activity and synergy in combination against a subset of study isolates. Imipenem exhibited predictable bactericidal activity against all isolates. The utility of combination regimens with novel agents requires further exploration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294108     DOI: 10.1592/phco.28.3.295

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

1.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Accuracy of empiric gentamicin dosing guidelines in neonates.

Authors:  Anna E Hitron; Yao Sun; Sarah B Scarpace
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

Review 3.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

4.  Novel biodegradable sandwich-structured nanofibrous drug-eluting membranes for repair of infected wounds: an in vitro and in vivo study.

Authors:  Dave Wei-Chih Chen; Jun-Yi Liao; Shih-Jung Liu; Err-Cheng Chan
Journal:  Int J Nanomedicine       Date:  2012-02-13

5.  In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates.

Authors:  Anku Goel; Varsha Gupta; Lipika Singhal; Sanjeev Palta; Jagdish Chander
Journal:  Indian J Med Res       Date:  2021-03       Impact factor: 5.274

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.